Alejandro Villagra

9PUBLICATIONS
32CO-AUTHORS
Predictive and prognostic markersInnate immunityRadiation therapyMolecular targetsGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Mar 17, 2025
Targeting prostate cancer by new bispecific monocyte engager directed to prostate-specific membrane antigen.

Gargi Das, Jakub Ptacek, Jana Campbell

|Nov 15, 2024
The HDAC6 inhibitor AVS100 (SS208) induces a pro-inflammatory tumor microenvironment and potentiates immunotherapy.

Damian Kovalovsky, Satish Noonepalle, Manasa Suresh

|Aug 16, 2023
Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition.

Satish Kumar R Noonepalle, Scott Grindrod, Nima Aghdam

|Dec 12, 2022
Radiotherapy Induces Innate Immune Responses in Patients Treated for Prostate Cancers.

Amrita K Cheema, Yaoxiang Li, Mary Ventimiglia

|Dec 24, 2021
Enhancing Therapeutic Approaches for Melanoma Patients Targeting Epigenetic Modifiers.

Maria Gracia-Hernandez, Zuleima Munoz, Alejandro Villagra

|Aug 21, 2020
Rational Design of Suprastat: A Novel Selective Histone Deacetylase 6 Inhibitor with the Ability to Potentiate Immunotherapy in Melanoma Models.

Satish Noonepalle, Sida Shen, Jakub Ptáček

Pageof 2

Frequent Collaborators

2 joint publications

Rohan Fernandes

2 joint publications

Christian Zevallos-Delgado

2 joint publications

Satish Noonepalle

2 joint publications

Anatoly Dritschilo